Imunon Inc (IMNN)

Sep 22, 2026

IMUNON, Inc. announced that its Independent Data Monitoring Committee (IDMC) has recommended the continued development of IMNN-001 in its Phase 2 minimal residual disease (MRD) study. The recommendation follows a favorable safety review, noting no new safety signals or severe adverse events, reinforcing the therapy's differentiated safety profile as an IL-12-based immunotherapy. This decision supports the ongoing pivotal Phase 3 OVATION 3 trial, especially after encouraging preliminary data from the MRD study suggested deeper anti-tumor activity and immune activation.

Sep 17, 2026

Imunon (NASDAQ: IMNN) awarded Executive Chairman Michael H. Tardugno 5,824 shares at a price of $1.47 per share on September 11, 2026. This transaction increased his total holdings in the company to 95,699 shares, representing approximately 6.1% of his overall ownership post-award. The filing provides transparent details about the award price and the executive's updated stake.

Sep 16, 2026

IMUNON, Inc. has entered a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to advance clinical development of its IL-12 DNA plasmid-based immunotherapy, IMNN-001. Under the agreement, NCI's Cancer Therapy Evaluation Program will assume regulatory sponsorship and evaluate IMNN-001 in new solid tumor indications and combination regimens, while IMUNON retains intellectual property. This collaboration allows IMUNON to expand the drug's application beyond ovarian cancer without diverting resources from its ongoing Phase III OVATION 3 trial.